Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 82 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	In-Vivo Activated T-Cell Depletion to Prevent GVHD				Phase III, Phase II				0705-20 IUCRO-0196 NCT00594308
	Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)				Phase III				385 BMT CTN 0402, U01 HL069294-05, NCT00406393
	Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder				Phase II, Phase I				FHCRC-1628.00 NCI-H02-0099, NCT00049634
	Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation				Phase II, Phase I				FHCRC-1825.00 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
	Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer				Phase II, Phase I				OHSU-HEM-05011-L OHSU-210, NCT00245037
	Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation				Phase II, Phase I				06-065 X05175, NCT00369226
	Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation				Phase II, Phase I				04U.115 NCT00429416
	Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Lymphoproliferative Malignancies				Phase II, Phase I				PDX-009 NCT00481871
	Phase I, Open-Label, Dose-Escalation, Safety and Pharmacokinetics (PK) Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)				Phase II, Phase I				D2782C00007 NCT00486265
	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease				Phase II, Phase I				BCM-H-19386 BCM-FAB, H 19386, NCT00625144


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute